Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways, much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback